Evidence map›Paper›PMID 28245345›Full record

ArticleJournal of gastroenterology and hepatology2017

Variations in primary sclerosing cholangitis across the age spectrum.

John E Eaton, Bryan M McCauley, Elizabeth J Atkinson, Brian D Juran, Erik M Schlicht, Mariza de Andrade, Konstantinos N Lazaridis

Abstract read
In one paragraph

Article in Journal of gastroenterology and hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. [Guidelines on the diagnosis and management of primary sclerosing cholangitis (2021)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
    Guideline
  2. Article
  3. Article
  4. STAT activation in regulatory CD4Immunity, inflammation and disease · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Cirrhotic patients and older people.World journal of hepatology · 2019
    Review
  11. Review
  12. The IBD and PSC Phenotypes of PSC-IBD.Current gastroenterology reports · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

John E EatonDivision of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Sciences, Rochester, Minnesota, USA.
Bryan M McCauleyDivision of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine and Sciences, Rochester, Minnesota, USA.
Elizabeth J AtkinsonDivision of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine and Sciences, Rochester, Minnesota, USA.
Brian D JuranDivision of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Sciences, Rochester, Minnesota, USA.
Erik M SchlichtDivision of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Sciences, Rochester, Minnesota, USA.
Mariza de AndradeDivision of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine and Sciences, Rochester, Minnesota, USA.
Konstantinos N LazaridisDivision of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Sciences, Rochester, Minnesota, USA.

Funding

PSC Resource Of Genetic Risk, Environment and Synergy Studies (PROGRESS)R01DK084960 · NIDDK · MAYO CLINIC ROCHESTER · PI LAZARIDIS, KONSTANTINOS N · 2010 to 2014
$3.0M
NIDDK NIH HHS R01 DK084960
6 · The paper itself

Abstract

BACKGROUND AND

aimPrimary sclerosing cholangitis (PSC) typically develops in middle-age adults. Little is known about phenotypic differences when PSC is diagnosed at various ages. Therefore, we sought to compare the clinical characteristics of a large PSC cohort based on the age when PSC was diagnosed.

methodsWe performed a multicenter retrospective review to compare the features of PSC among those diagnosed between 1-19 (n = 95), 20-59 (n = 662), and 60-79 years (n = 102).

resultsThose with an early diagnosis (ED) of PSC were more likely to have small-duct PSC (13%) than those with a middle-age diagnosis (MD) (5%) and late diagnosis (LD) groups (2%), P < 0.01, and appeared to have a decrease risk of hepatobiliary malignancies: ED versus MD: hazard ratio (HR), 0.25; 95% confidence interval (CI) 0.06-1.03, and ED versus LD: HR, 0.07; 95% CI 0.01-0.62. Cholangiocarcinoma was diagnosed in 78 subjects (ED n = 0, MD n = 66, and LD n = 12) and was more likely to be diagnosed within a year after the PSC diagnosis among those found to have PSC late in life: ED 0% (0/95), MD 2% (14/662), and LD 6% (6/102), P = 0.02. Similarly, hepatic decompensation was more common among those with LD-PSC versus younger individuals: LD versus MD: HR, 1.64; 95% CI 0.98-2.70, and LD versus ED: HR, 2.26; 95% CI 1.02-5.05.

conclusionsThose diagnosed with PSC early in life are more likely to have small-duct PSC and less likely to have disease-related complications. Clinicians should be vigilant for underlying cholangiocarcinoma among those with PSC diagnosed late in life.

Indexed as

AdolescentAdultAgedAge DistributionBile Duct NeoplasmsChildChild, PreschoolCholangiocarcinomaCholangitis, SclerosingCohort StudiesEarly DiagnosisFemaleHumansInfantMaleMiddle Agedcholangiocarcinomainflammatory bowel diseaseliver transplantationprimary sclerosing cholangitis

Identifiers

PMID28245345
PMCPMC5573663

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.